Johnson & Johnson's (J&J) planned takeover of Aragon Pharmaceuticals Inc. for $650 million in cash and $350 million more in potential milestone payments brings aboard the Phase III-ready ARN-509 for castration-resistant prostate cancer (CRPC) behind the pharma firm's approved androgen inhibitor Zytiga (abiraterone acetate) for the same indication. Read More
Tacking toward the middle, the Supreme Court gave the FTC some berth Monday in challenging pay-for-delay settlements between generic and brand drugmakers, but it closed the hatch on a "quick look" approach that would presume all such agreements are unlawful. Read More
Although the official start of summer is still a few days away, the biotech world already is producing a bumper crop of initial public offerings (IPO). Read More
News of at least a three quarter delay in seeking regulatory approval for Fabry disease candidate migalastat unsurprisingly sent shares of Amicus Therapeutics Inc. falling 24 percent in Monday morning trading, but reports of the firm's recent meeting with the FDA left room for optimism for the Glaxosmithkline plc-partnered molecular chaperone. Read More
DUBLIN, Ireland – In a sharp slap in the face to the company's management and its would-be acquirer Royalty Pharma, shareholders in Elan Corp. plc voted down three of four motions tabled at an extraordinary general meeting Monday. Read More
• Transition Therapeutics Inc., of Toronto, said Eli Lilly and Co., of Indianapolis, exercised its option to assume all development and commercialization rights to Type II diabetes drug candidate TT-401. Read More
• Array Biopharma Inc., of Boulder, Colo., said interim results from an ongoing combination trial of ARRY-520 with Kyprolis (carfilozomib) in patients with relapsed or refractory multiple myeloma (MM) who are refractory or intolerant to Velcade (bortezomib) were reported at the European Hematology Association meeting. Read More
• Eisai Inc., of Woodcliff Lake, N.J., expanded its Hatfield, UK-based EMEA (Europe, Middle East, Africa, Russia and Oceania) Knowledge Centre with a additional global packaging capability. Read More
• Ipsen SA, of Paris, relased results of an international Phase IIIB study, PRIMARYS, assessing an investigational use of Somatuline Autogel (lanreotide) 120 mg as first-line therapy in newly diagnosed acromegaly patients with a macroadenoma. Read More